Parallax Volatility Advisers
NKTR icon

Parallax Volatility Advisers’s Nektar Therapeutics NKTR Stock Holding History

Parallax Volatility Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-306
Closed -$82K – 2179
2021
Q3 		$82K Buy
+306
New +$73.6K ﹤0.01% 1787
2019
Q2 		– Sell
-72
Closed -$36K – 3342
2019
Q1 		$36K Sell
72
-2,978
-98% -$1.76M ﹤0.01% 2426
2018
Q4 		$1.5M Sell
3,050
-14,827
-83% -$8.95M ﹤0.01% 1166
2018
Q3 		$16.3M Sell
17,877
-307
-2% -$262K 0.02% 345
2018
Q2 		$13.3M Buy
18,184
+18,183
+1,818,300% +$21M 0.02% 365
2018
Q1 		$2K Sell
1
-1,503
-100% -$1.94M ﹤0.01% 2035
2017
Q4 		$1.35M Buy
+1,504
New +$890K ﹤0.01% 1071

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Parallax Volatility Advisers's NKTR Position: Q4 2021 in Review

Parallax Volatility Advisers sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 306 shares — an estimated $82K sold.

Parallax Volatility Advisers first reported a position in NKTR in Q4 2017 and held it in 7 quarters. The position peaked at $16.3M in Q3 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Parallax Volatility Advisers reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 306 Nektar Therapeutics shares in Q4 2021, an estimated $82K.
  • Parallax Volatility Advisers first reported a position in Nektar Therapeutics in Q4 2017 and held it in 7 quarters.
  • Parallax Volatility Advisers's Nektar Therapeutics position peaked at $16.3M in Q3 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Parallax Volatility Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.